BICYCLIC TRITERPENOID IRIPALLIDAL AS A NOVEL ANTI-GLIOMA AND ANTI-NEOPLASTIC THERAPY IN VITRO

摘要

This invention relates to a Bicyclic triterpenoid Iripallidal as a novel anti-glioma and anti neoplastic agent in vitro, having the composition [(-) (6R, 10S, US, 18R, 22S)-26 Hydroxy -22-∞ methylcyloirid-16-enal NSC 631939], wherein it binds to Ras GRP3, a phorbol ester receptor that links DAG/phorbolester signaling with Ras activation and induces phosphorylation of ER Kl/2 in a Ras dependent manner, reducing proliferation of cancer cell lines to the extent of 50-70%.